Syndax Leverages Novel IP for Cash, Phase II HDAC
This article was originally published in Start Up
Executive Summary
Syndax has parlayed its HDAC/nuclear receptor ligand combo IP into a $40 million Series A backed by Domain and MPM and a licensing deal with Bayer-Schering.